Genetic variants affecting adrenoceptors have been suggested to influence body fatness. A putative gain-offunction polymorphism in the b 1 -adrenoceptor was recently discovered (Gly389Arg ADRB1). We examined the association between Gly389Arg ADRB1 and obesity status in a large cohort of well-characterized individuals. METHODS: First, a large cohort of 931 Caucasian women (55.0 AE 12.2 y) were genotyped for Gly389Arg ADRBb1 and we examined the association of the Arg allele with body weight and BMI (Gly=Gly, n ¼ 54; Gly=Arg, n ¼ 360; Arg=Arg, n ¼ 517). To further examine phenotypes regulating energy balance and body fatness, we examined the contribution of the Arg allele to body composition (DEXA), fat distribution (CT scan), resting energy expenditure, energy and macronutrient intake, maximal oxygen capacity, and physical activity in a subsample of 214 women from the main cohort that had been carefully characterized (Gly=Gly, n ¼ 19; Gly=Arg, n ¼ 82; Arg=Arg, n ¼ 113). RESULTS: In the entire cohort (n ¼ 931), allele frequencies were 0.25 and 0.75 for the Gly and Arg alleles, respectively. In this cohort, we found that each Arg allele was associated with greater body weight of 2.91 kg (P ¼ 0.01) and BMI of 0.86 kg=m 2 (P ¼ 0.05). Accordingly, in the subsample of women, each Arg allele was associated with greater fat mass (3.71 kg; P ¼ 0.008). Other phenotypes were not significantly associated with the presence of the Arg allele. CONCLUSIONS: This is the first study to investigate the relationship between the Gly389Arg ADRB1 variant and obesity. We found that the Arg allele is associated with greater body weight and BMI in Caucasian women due to a greater fat mass.
Introduction
Obesity is the result of an interaction between environmental and genetic components, in which the genetic components are poorly understood. Several genetic variants affecting the family of adrenoceptors have been shown to influence obesity-related phenotypes. For instance, the Trp64Arg polymorphism in the b 3 -adrenoceptor is associated with low energy expenditure, impaired fat oxidation and excess accumulation of body fat. 1 -4 However, results are contradictory among investigators. The b 2 -adrenoceptor has several polymorphisms, among which the Gln27Glu ADRB2 variant has been found to be associated with obesity. 5 In a study by Large et al, 5 homozygotes for the Glu allele displayed a greater fat mass than Gln homozygotes or heterozygotes. However, others have failed to find such associations. 6 -8 The b 1 -adrenoceptor is a member of the G-proteincoupled receptors, with epinephrine and norepinephrine being endogenous agonists. Stimulation of the b 1 -adrenoceptor mediates energy expenditure 9 and lipolysis 10 in human adipocytes. A common genetic variant of the human b 1 -adrenoceptor gene that codes for a replacement of glycine-389 with an arginine residue (G1y389Arg ADRB1) in the C-terminal intracellular G-protein coupling domain was recently identified. 11 When studied in vitro, the Arg-389 receptor displayed enhanced receptor-G s interaction, functionally leading to increased adenylyl cyclase activity compared to the Gly-389 receptor. It is still not clear, however, whether this b 1 -adrenoceptor affects lipolysis, fat storage or energy balance in vivo.
To our knowledge, this is the first population-based study to examine the association of Gly389Arg of the b 1 -adrenoceptor gene with several obesity-related phenotypes. To accomplish this objective, we used two experimental association-based analytical approaches. We first examined the association of the Arg variant with body weight and body mass index, in a large cohort of 931 unrelated Caucasian women. Second, in a subset of 214 women from the main group that had been better characterized for body composition and energy metabolism, we examined the association of the Arg allele with phenotypes involved in the regulation of fat mass.
Methods

Subjects
Data of for this study were derived from the screening and=or baseline data obtained in the course of several different intervention studies conducted at the University of Vermont over the course of the last 5 y. That is, over the course of these studies 931 Caucasian women were screened (physical examination, medical history, age, body weight, height) to potentially participate in several exercise and=or weight loss protocols (non-obese women for exercise studies; overweight or obese women for weight loss intervention). Out of this larger cohort (n ¼ 931), 214 were actually enrolled in exercise or weight loss protocols. Data obtained at screening (all subjects) and at baseline (subsample) were pooled together in a large dataset, and all subjects were genotyped for the Gly389Arg variant of the b 1 -adrenoceptor gene. 2 ) and the variant allele. The subset of 214 of these women who actually enrolled in a protocol was thus better characterized for with respect to obesity-related phenotypes. In these unrelated women (age AE s.d., 52.3 AE 17.6 y, range 20 -87 y; and BMI AE s.d., 28.1 kg=m 2 range 16 -59), we thus studied the association of the variant allele with the more precisely measured phenotypes including: body composition, body fat distribution, energy expenditure, fitness level and energy intake. Subjects were recruited by local advertisement. Inclusion criteria were: (1) non-smokers (cigarette consumption could affect energy metabolism); (2) not taking any medication that could affect cardiovascular function or metabolism, (3) non-diabetic (affects glucose metabolism); and (4) absence of cardiovascular diseases, hypertension or any other diseases that could render exercise or weight loss at risk (diastolic blood pressure > 90 mmHg). Subjects gave their written informed consent to be genotyped and to be included in this study. Because no reports have been published on the Gly389Arg ADRB1 variant in other populations, we also genotyped individuals from other ethnicities to compare the allele frequencies of these populations and Caucasian women. Pima Indians were from the Gila River Indian Community in Phoenix, AZ, MexicanAmericans were recruited from San Antonio, TX, as part of the San Antonio Diabetes Family Study, and Chinese subjects were recruited from mainland China. All were unrelated individuals. in the presence of 10% dimethylsulfoxide (Sigma Chemical, St Louis, MO, USA). The G to C transition at nucleotide position 1165 of the b 1 -adrenoceptor gene resulted in the loss of a BstNl restriction site. The resulting 108 bp products were digested with BstN1. The digested products were subjected to electrophoresis through a 3% agarose gel (NuSieve 3 : 1 agarose, FMC bioproducts, Rockland, ME, USA) containing 250 nM ethidium bromide. The Gly389 ADRB1 PCR product remained 108 bp after digestion with BstN1, while the Arg-389 ADRB1 PCR product was cleaved into two products of 66 and 42 bp. The products were visualized in the gel under UV translumination. Genotypes were scored by two independent observers. Body composition and body fat distribution Body weight and height. Body weight was determined using a metabolic scale (Scale-Tronix, Inc., Wheaton, IL, USA) with the volunteer clothed in a hospital gown. Height was measured using a tape measure attached to the wall with the volunteer in stocking feet.
Genotype analysis
Dual energy X-ray absorptiometry (DEXA). Fat mass and fat-free mass were assessed in a supine position, using dualenergy X-ray absorptiometry (DEXA, model DPX-L; LUNAR Radiation Corp, Madison, WI, USA) as previously described. 12, 13 Computed tomography (CT). Visceral adipose tissue and subcutaneous adipose tissue mass was measured by computed tomography (CT) as previously described 14 using a High Speed Advantage CT scanner (General Electric Medical Systems, Milwaukee, WI, USA). The subjects were examined Gly389Arg ADRB1 and obesity IJ Dionne et al in the supine position with both arms stretched above their head. The position of the scan was established at the L4 -L5 level using a scout image of the body. Visceral adipose tissue area was quantified by delineating the intra-abdominal cavity at the internal most aspect of the abdominal and oblique muscle walls surrounding the cavity and the posterior aspect of the vertebral body. Adipose tissue was highlighted and computed using an attenuation range of 7 190 to 7 30 Hounsfield Units. The subcutaneous adipose tissue area was quantified by highlighting adipose tissue located between the skin and the external most aspect of the abdominal muscle wall.
Resting energy expenditure (REE) and respiratory quotient (RQ) REE and RQ were measured by indirect calorimetry for 45 min as previously described, 14 using the ventilated hood technique, following an overnight 12 h fast at the General Clinical Research Center (GCRC) of University of Vermont. Respiratory gas analysis was performed using a Deltatrac metabolic cart (Sensormedics, Yorba Linda, CA, USA). REE (kcal= day) was calculated from the equation of Weir. 15 The test -retest correlation coefficient within one week is 0.90 for REE in our laboratory.
Maximal oxygen consumption (VO 2max ) VO 2max was determined from an incremental exercise test to exhaustion on a treadmill, as previously described. 16 Briefly, after an initial 3 min warm-up, the speed was set so that the heart rate would not exceed 70% of the age-predicted maximal heart rate (220 7 age(y). Thereafter, the speed was held constant and the grade was increased by 2.5% every 2 min. The criteria for achieving VO 2max were (1) a respiratory exchange ratio > 1.0, or (2) a heart rate at above the agepredicted workload. Test -retest conditions for nine individuals (on two occasions retested 1 week apart) yielded an intraclass correlation of 0.94 and a coefficient of variation of 3.8% in our laboratory.
Energy intake
Energy intake was measured as previously described. 17 Briefly, total daily food intake was assessed using the 3 day food record (2 week-days and 1 weekend day). Subjects were trained about how to measure, weigh and record portion sizes. Food scales and measuring instruments were provided to all subjects. Nutritional assessment was conducted using the Nutritionist III software package (Version 4.0, N-Squared Computing, Salem, OR, USA).
Leisure time physical activity (LTA) Leisure time physical activity was measured by the Minnesota LTA questionnaire. 18 This is an interviewer-administered questionnaire that assesses daily physical activity accumulated during leisure time and household physical activity over the past 12 months. Trained personnel administered the questionnaire during a 20 min interview. Leisure time physical activity was calculated based on the number of months spent completing the specific activity per year, the average number of times for the specific activity each month, the total time of each physical activity session, and the activity specific intensity code. The test -retest correlation coefficient over a month has been shown to be 0.92 when tested in older women and men. 19 Blood pressure Supine diastolic and systolic blood pressure were determined as the average of the last four readings of five taken every minute from a Dinamap automatic cuff machine (Critikon, Johnson & Johnson Co., Tampa, FL, USA) as previously described. 20 Measurements were taken 3 h after the subject was admitted for an overnight stay at the General Clinical Research Center.
Blood lipids
After a 12 h fast, blood samples were obtained in the morning from an antecubital vein and stored into vacutainer tubes containing EDTA. Cholesterol and triglyceride concentrations in plasma and lipoprotein fractions were determined by enzymatic methods. 21, 22 HDL-cholesterol fraction was measured in plasma supernatant after precipitation with dextran sulfate and magnesium sulfate. 23 The formula of Friedewald et al 24 was used to calculate plasma LDLcholesterol concentrations.
Statistical analyses
All values are presented as mean AE s.d. (means were adjusted for covariate(s) when appropriate). Since a trend of increasing obesity and obesity-related phenotype values appeared to be stepwise (ie variables increasing with the number of alleles), a co-dominant model was used. We examined the contribution of Arg alleles to obesity-related phenotypes, using a linear regression model with the number of Arg alleles as a quantitative variable. Age was used as a covariate for all body composition variables. Fat mass and fat-free mass were used as covariates for REE and fat mass for visceral fat. The difference in the frequency of obesity for carriers vs noncarriers of the Arg allele was examined using a 2Â2 chisquare analysis with obesity defined as a BMI ! 30 kg=m 2 .
25
The proportion of the risk of being obese in the Arg carriers that could be attributed to the Arg allele (attributable risk in the exposed) was calculated as following: attributable risk ¼ (risk 1 7 risk 0)=risk 1, where 'risk 1' is the risk of being obese in the combined Gly=Arg and Arg=Arg groups, and 'risk 0' is the risk of obesity in the Gly=Gly group.
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Results
Allele and genotype frequencies
The allele frequencies for the 931 unrelated Caucasian females genotyped were 0.25 and 0.75 for the Gly and Arg alleles, respectively. Despite the Gly389 allele being the less common allele, we have designated this allele as the normal allele because it is the sequence that was initially reported (Genbank assession no. J03019 26 ). The genotype frequencies were in accordance with Hardy -Weinberg equilibrium, with 5.8% of our subjects homozygous for the normal allele (Gly=Gly), 55.5% homozygous for the variant allele (Arg=Arg) and 38.7% heterozygotes (Gly=Arg). We also genotyped individuals from other ethnicities and found that the frequency of the Arg allele was higher in Mexican-Americans, Pima Indians, and Chinese but lower in African-Americans compared with Caucasian women (Table 1) .
Body weight and body mass index (BMI) in the total cohort (n ¼ 931) Subjects with the Arg allele were significantly more obese than non-carriers (Table 2) . Using a co-dominant model, each Arg allele was associated with a higher body weight (2.91 kg; P ¼ 0.01) and BMI (0.86 kg=m 2 ; P ¼ 0.05) as well as a greater standing height (0.71 cm; P ¼ 0.03).
Using a BMI cut-off point of 30 kg=m 2 for obesity, as recommended by the World Health Organization, 25 66.6% of Gly=Arg and 67.6% of Arg=Arg would be classified as obese, whereas only 53.7% of the non-carriers of the Arg allele (Gly=Gly) would be considered obese. Since frequencies of obesity were similar between subjects with the Gly=Arg and Arg=Arg genotypes, these two groups were pooled together for a 2Â2 chi-square analysis of obesity frequency (Gly=Gly vs Gly=Arg þ Arg=Arg; P ¼ 0.03; Figure  1 ). All groups also included approximately 10% overweight individuals (BMI between 25 and 30 kg=m 2 ) and the remaining individuals (23% of Arg carriers and 36% of normal homozygotes were considered lean (BMI 25 kg=m 2 ). We also calculated the attributable risk of obesity due to the presence of the Arg allele. We found that the proportion of the risk of obesity in the exposed attributed to the Arg allele was 0.20.
Obesity-related phenotypes in the subset of women (n ¼ 214) As with the larger cohort, the Arg allele was associated with significantly greater body weight and BMI in the subset of subjects who were more extensively phenotyped. As shown in Table 3 , each Arg allele was associated with greater body weight (5.65 kg; P ¼ 0.006), BMI (1.67 kg=m 2 ; P ¼ 0.025), and fat mass (3.71 kg; P ¼ 0.008). Fat-free mass was also greater in carriers of the Arg allele, but the effect was not significant after adjusting for fat mass (not shown). Age, height, visceral fat (adjusted for total fat), resting energy expenditure (adjusted for fat mass and fat-free mass), RQ, VO 2max leisure time physical activity, and energy intake were not significantly associated with ADRB1 genotype. Heart rate, blood pressure, fasting glucose and insulin and lipid profile were not different among genotypes (Table 4) .
Discussion
This study is the first to examine obesity-related phenotypes and a recently discovered putative gain-of-function variant ) and non-obese (BMI < 30 kg=m 2 ) for each genotype. P-value ¼ 0.03 for differences between carriers and non-carriers.
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IJ Dionne et al in the b 1 -adrenoceptor that codes for the replacement of glycine-389 with arginine. 11 We used two different and complementary approaches to study the relationship between the G1y389Arg ADRB1 variant and body fatness. First, we genotyped a large cohort of 931 Caucasian women for Gly389Arg ADRB1 and examined the association of the variant with body weight and BMI. Second, because body fatness is regulated by the long-term balance between energy intake and energy expenditure, we examined the variant's association with direct measures of body fat and energy balance phenotypes (energy expenditure, physical activity, energy intake, etc.) in a subsample of 214 of these women.
The new findings are: (1) the Arg allele is significantly associated with a greater body weight and BMI in both heterozygous and homozygous states, (2) the higher body weight and BMI appear to be attributable, in large part, to greater fat mass as measured by DEXA. Interestingly, we also observed an effect of the variant on standing height. This association suggests that subjects with the variant allele may have been more obese in childhood since it is well known that overnutrition during childhood is related to increased linear growth rate and adult height. 27 However, the greater height accounted only in part for the higher body weight and fat mass since BMI and percentage fat, which are two variables independent of height, were also greater in individuals with the Arg allele.
We employed an additional strategy to examine the association between the Gly389Arg ADRB1 and obesity. Based on recent guidelines for the classification of overweight and obese individuals in the United States and Canada, 25 we observed that 66.6% of heterozygotes and 67.6% of homozygotes for the variant allele were categorized as obese (BMI ! 30 kg=m 2 ), whereas only 53.7% of normal homozygotes were classified as obese (P ¼ 0.03). We also calculated the proportion of the risk of being obese among the carriers of the Arg allele that could actually be attributed to the presence of the Arg allele. We observed that 20% of the risk for obesity was attributed to this allele. Collectively, these results suggest that the Arg allele is associated with an increased prevalence of obesity in Caucasian women.
The mechanism(s) whereby the Gly389Arg ADRB1 variant increases susceptibility to a greater fat mass are unknown. The b 1 -adrenoceptor is one of the G proteincoupled receptors involved in the regulation of lipolysis in human adipocytes. 9, 10, 28 Evidence from in vitro expression studies suggests that the substitution of glycine to arginine at position 389 is a gain-of-function polymorphism. 11 Thus, we would expect that this gain-of-function All values are mean AE s.d. *P < 0.05; **P < 0.01. REE, resting energy expenditure; LTA, leisure time activity. a The Arg effect is the number of units that are added per Arg allele to the control (Gly=Gly) value, as predicted by a linear regression model. Body composition variables were all adjusted for age; resting energy expenditure was adjusted for age, fat mass and fat-free mass, and visceral fat was adjusted for age and fat mass. Table 4 Heart rate, blood pressure, fasting glucose and insulin and lipid profile in normal homozygotes, heterozygotes and homozygotes for the Gly389Arg ADRB1 variant allele in Caucasian women Gly389Arg ADRB1 and obesity IJ Dionne et al polymorphism may possibly lead to an increase in lipolysis, and potentially, a decreased fat mass in Gly389Arg ADRB1 carriers. However, we observed an opposite association in the Gly389Arg ADRB1 carriers who showed a higher fat mass. One possibility to explain this phenomenon is that persistent stimulation of the b 1 -adrenoceptor leads to increased serine phosphorylation of the intracellular C-terminus by b-adrenergic receptor kinase (BARK) and cAMP-dependent protein kinase, which results in diminished responsiveness of the b 1 AR=adenylyl cyclase signal transduction system (ie desensitization). 29 Speculatively, this gain-of-function polymorphism may lead to increased desensitization in adipocytes in vivo, which chronically would lead to decreased lipolysis and an increase in fat mass and obesity in individuals carrying this polymorphism. Clearly physiological studies will be necessary to define the functional consequences of this variant in vivo.
Lipolysis has been shown to be increased in visceral fat cells of obese individuals, and it has been suggested that this could contribute to the metabolic disturbances observed in upper-body obesity. 30 ; not shown). However, the differences in visceral fat between groups did not persist after statistical control for differences in total fat mass. Furthermore, no difference was found between groups for blood pressure, plasma cholesterol or triglycerides (Table 4) , reinforcing the possibility that lipolysis is not increased in carriers of the Gly389Arg ADRB1 variant. This suggests that carriers of the variant accumulate more total body fat mass, but do not selectively deposit visceral fat in the abdominal cavity, independent of total fat mass.
Body composition is regulated by the long-term balance between the components of energy intake and energy expenditure. 31 We thus examined energy balance components (ie energy expenditure components, substrate oxidation and energy intake) in an attempt to determine the mechanisms that may increase susceptibility to obesity in Arg carriers. Contrary to our expectations, we found no differences in adjusted resting metabolic rate, leisure time physical activity, RQ, VO 2max , and energy intake among genotypes (Table 2) . Moreover, despite the expression of b 1 -adrenoceptors in heart and smooth muscle (in addition to adipocytes), we found no differences between pulse or blood pressure in carriers and non-carriers of the Gly389Arg ADRB1 variant. These findings, however, should not be interpreted to suggest an absence of effect of this variant on components of energy balance. Clearly, a chronic energy imbalance was operative at some point in time to account for the greater fat mass in carriers of the Gly389Arg ADRB1 variant. We would, however, suggest that compensatory mechanisms to buffer further weight gain may be obscuring the primary metabolic defect of the Gly389Arg ADRB1 variant. That is, it is known that as individuals gain body fat, compensatory increases in resting metabolic rate, fatfree mass and fat oxidation are noted in an effort to protect against further weight gain. 9 Thus, in this study, it is likely that we detected the consequences of an energy imbalance in carriers of the variant (ie greater fat mass), but at this point we are unable to identity causative factors underlying the greater fat mass in carriers of the variant. We have observed a similar phenomenon in obese carriers of the Trp64Arg variant of the b 3 -adrenoceptor. In the obese state, there were no differences in resting metabolic rate (RMR) and visceral fat between carriers and non-carriers of the variant. However, after a similar amount of weight loss, we observed that carriers had a lower RMR and greater visceral fat. 14, 32 Similar prospective studies of non-obese or post-obese subjects will be required to further study the effects of the Gly389Arg ADRB1 variant on metabolic parameters and energy balance.
Association studies of unrelated individuals are subject to stratification bias caused by unrecognized admixture and potential differences in allele frequencies and phenotypes (unrelated to the measured genotype) between the admixed. 33 Although we cannot rule out this possibility as the source of the significant associations with obesity phenotypes, we believe it to be unlikely since only Caucasian women were ascertained and studied. Similarly, we cannot rule out the possibility that our significant associations were due to type 1 error and=or multiple comparisons. However, we do not believe this to be likely since all phenotypes tested were based upon a priori hypothesis, and analyses of two overlapping subsets of study subjects yielded essentially identical results.
Further evidence of the involvement of this variant in obesity and related phenotypes would be if the b 1 -adrenoreceptor were located in a region found to be linked to these traits in a genome-wide scan. To date no linkages in genomewide screens for obesity have been reported on chromosome 10q24 -26. We cannot rule out the possibility that this variant is in linkage disequilibrium with the actual diseasecausing variant. Interestingly, the a 2a -adrenoceptor is tightly linked with the b 1 -adrenoceptor on chromosome 10q24 -q26. 34 Indeed, one group 35 has shown an association between trunk to extremity skinfolds ratio and a polymorphism in the a 2a -adrenoceptor. Because of linkage disequilibrium, this association may have been driven by variation in the b 1 -adrenoceptor, or our data could have been driven by variation in the a 2a -adrenoceptor.
In conclusion, we found evidence of an association between the Gly389Arg ADRB1 variant with greater body weight, BMI, and fat mass in Caucasian women. We also found a higher frequency of obesity in subjects with the variant. Although this very common amino acid substitution appears to be a gain-of-function mutation in vitro, the Gly389Arg ADRB1 variant may favor a greater accumulation of fat mass in a gene-dose-dependent manner. However, the mechanisms whereby this variant contributes to obesity are presently unknown.
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